Oscar Health (NYSE:OSCR) Insider Sells $216,306.46 in Stock

Oscar Health, Inc. (NYSE:OSCR) insider Adam Mcananey sold 9,859 shares of the company’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $21.94, for a total value of $216,306.46. Following the transaction, the insider directly owned 218,096 shares of the company’s stock, valued at approximately $4,785,026.24. This trade represents a 4.32% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Oscar Health Stock Performance

Shares of OSCR stock opened at $24.59 on Friday. The company’s fifty day simple moving average is $18.39 and its 200-day simple moving average is $16.06. The company has a quick ratio of 1.11, a current ratio of 1.11 and a debt-to-equity ratio of 0.26. The firm has a market cap of $7.41 billion, a PE ratio of -41.68, a P/E/G ratio of 1.71 and a beta of 2.37. Oscar Health, Inc. has a 12 month low of $10.69 and a 12 month high of $25.58.

Oscar Health (NYSE:OSCR) last announced its quarterly earnings data on Wednesday, May 6th. The company reported $2.07 EPS for the quarter, topping analysts’ consensus estimates of $1.11 by $0.96. The business had revenue of $4.65 billion for the quarter, compared to analyst estimates of $4.90 billion. Oscar Health had a negative net margin of 0.30% and a negative return on equity of 3.26%. The firm’s revenue for the quarter was up 52.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.92 earnings per share. Equities research analysts expect that Oscar Health, Inc. will post 0.47 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on OSCR shares. Weiss Ratings reissued a “sell (d)” rating on shares of Oscar Health in a research report on Tuesday, April 21st. Wall Street Zen lowered Oscar Health from a “strong-buy” rating to a “buy” rating in a report on Saturday. Zacks Research upgraded Oscar Health from a “hold” rating to a “strong-buy” rating in a report on Thursday, May 7th. Wolfe Research began coverage on Oscar Health in a report on Tuesday, May 5th. They set a “peer perform” rating on the stock. Finally, Raymond James Financial upgraded Oscar Health from a “market perform” rating to an “outperform” rating and set a $18.00 target price on the stock in a report on Thursday, February 12th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $20.22.

Oscar Health News Roundup

Here are the key news stories impacting Oscar Health this week:

• Positive Sentiment: Wells Fargo upgraded Oscar Health from “strong sell” to “hold”, easing bearish sentiment even though its $20 target remains below the current share price. Zacks.com
• Positive Sentiment: Oscar Health’s recent earnings showed a major EPS beat, which supports the stock’s fundamental story despite revenue coming in below estimates.
• Neutral Sentiment: A company co-founder shifting into an advisory leadership role looks like an internal reorganization rather than a disruptive change. Oscar Health Co-Founder Shifts to Advisory Leadership Role
• Neutral Sentiment: Multiple insiders, including CFO Richard Scott Blackley and CAO Victoria Baltrus, sold shares under pre-planned 10b5-1 programs to cover tax obligations on vested equity awards, which is less concerning than discretionary selling.
• Negative Sentiment: Director Mario Schlosser sold 34,120 shares, the largest insider sale in the latest batch, which may pressure sentiment even though it was pre-arranged.

Institutional Investors Weigh In On Oscar Health

Large investors have recently made changes to their positions in the stock. Quarry LP boosted its holdings in shares of Oscar Health by 439.8% in the 3rd quarter. Quarry LP now owns 1,803 shares of the company’s stock valued at $34,000 after buying an additional 1,469 shares during the last quarter. Tsfg LLC acquired a new stake in shares of Oscar Health in the 3rd quarter valued at approximately $38,000. Jones Financial Companies Lllp boosted its holdings in shares of Oscar Health by 7,473.3% in the 1st quarter. Jones Financial Companies Lllp now owns 2,272 shares of the company’s stock valued at $30,000 after buying an additional 2,242 shares during the last quarter. Strs Ohio acquired a new stake in shares of Oscar Health in the 1st quarter valued at approximately $30,000. Finally, Fifth Third Bancorp boosted its holdings in shares of Oscar Health by 148.7% in the 4th quarter. Fifth Third Bancorp now owns 2,363 shares of the company’s stock valued at $34,000 after buying an additional 1,413 shares during the last quarter. Institutional investors and hedge funds own 75.70% of the company’s stock.

Oscar Health Company Profile

Oscar Health, trading on the New York Stock Exchange under the ticker OSCR, is a technology-driven health insurance company headquartered in New York, New York. Founded in 2012 by Mario Schlosser, Joshua Kushner and Kevin Nazemi, the company was built with the goal of simplifying healthcare coverage and enhancing member experience. Oscar leverages a proprietary digital platform to streamline plan enrollment, claims administration and member support, distinguishing itself in the individual, family and small group insurance markets.

The company’s primary products include on-exchange individual and family medical plans under the Affordable Care Act, off-exchange plans, as well as Medicare Advantage offerings.